Register entry
- Registered sites
- 19
- Active NDC listings
- 126
- Labeller names
- 3
- Live patents
- 63
- Exclusivities
- 5
- Shortage listings
- 3
- Countries
- 9
- Base
- United Kingdom
Authorisation
Registered operations
Analytical testing19Active ingredient (API) manufacture6Labelling13Finished drug manufacture15Packaging15particle size reduction3sterilize8
Sites
Registered establishments
19| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| GlaxoSmithKline Biologicals SA | Rue de l'Institut 89, Rixensart, B-1330, Belgium (BEL) | Analytical testing, Labelling, Finished drug manufacture, Packaging, sterilize | 3002875226372748392 |
| GlaxoSmithKline Biologicals SA | Avenue Fleming 20, Wavre, 1300, Belgium (BEL) | Analytical testing, Labelling, Finished drug manufacture, Packaging, sterilize | 3003973577376996273 |
| ID Biomedical Corporation of QuebecRegistrant: GlaxoSmithKline Biologicals SA | 2323 du Parc Technologique Blvd., Ste-Foy, Quebec G1P 4R8, Canada (CAN) | Analytical testing, Labelling, Finished drug manufacture, Packaging, sterilize | 3004835647243368284 |
| SmithKline Beecham Pharma GmbH & Co. KG (dba GlaxoSmithKline Biologicals)Registrant: GlaxoSmithKline Biologicals SA | Zirkusstrabe 40, Dresden, Sachsen D-01069, Germany (DEU) | Analytical testing, Finished drug manufacture, Packaging, sterilize | 3004835618344031009 |
| GSK Vaccines GmbHRegistrant: GlaxoSmithKline Biologicals SA | Emil-von-Behring-Str. 76, Marburg, 35041, Germany (DEU) | Analytical testing, Finished drug manufacture, Packaging | 3001314775314891029 |
| Glaxo Wellcome S.A.Registrant: GlaxoSmithKline plc | Avda. Extremadura, 3, Aranda De Duero, 09400, Spain (ESP) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3004195227462027152 |
| Glaxo Wellcome ProductionRegistrant: GlaxoSmithKline plc | Zone Industrielle No. 2, 23 Rue Lavoisier, Evreux, Eure 27000, France (FRA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging, particle size reduction | 3002807436383861593 |
| GlaxoSmithKline BiologicalsRegistrant: GlaxoSmithKline Biologicals SA | 637 Rue des Aulnois, Saint-Amand Les Eaux, 59230, France (FRA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3014752610393016621 |
| Glaxo Operations UK LtdRegistrant: GlaxoSmithKline plc | Harmire Road, Barnard Castle, County Durham DL12 8DT, United Kingdom (GBR) | Analytical testing, Labelling, Finished drug manufacture, Packaging, sterilize | 3002807078228472833 |
| Glaxo Operations UK LtdRegistrant: GlaxoSmithKline plc | Cobden Street, Montrose, Angus DD10 8EA, United Kingdom (GBR) | Analytical testing, Active ingredient (API) manufacture | 3003215057424738227 |
| Glaxo Operations UK LtdRegistrant: GlaxoSmithKline plc | Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom (GBR) | Analytical testing | 3009763376218783633 |
| Glaxo Operations UK LtdRegistrant: GlaxoSmithKline plc | Priory Street, Ware, Hertfordshire SG12 0DJ, United Kingdom (GBR) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging, particle size reduction | 3003262904517226676 |
| GlaxoSmithKline Vaccines SrlRegistrant: GlaxoSmithKline Biologicals SA | LOCALITA' BELLARIA, SOVICILLE (ROSIA ), 53018, Italy (ITA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3006738517445558679 |
| GlaxoSmithKline Manufacturing SpARegistrant: GlaxoSmithKline plc | Strada Provinciale 343 Asolana 90, Torrile, San Polo, Parma 43056, Italy (ITA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging, sterilize | 3002807114338471078 |
| GSK Vaccines S.r.l.Registrant: GlaxoSmithKline Biologicals SA | Via Fiorentina 1, Siena, SI 53100, Italy (ITA) | Analytical testing | 3007780504442017901 |
| Glaxo Wellcome Manufacturing Pte. LtdRegistrant: GlaxoSmithKline plc | 1, Pioneer Sector 1, Jurong, 628413, Singapore (SGP) | Analytical testing, Active ingredient (API) manufacture, particle size reduction | 3002807079595295577 |
| GlaxoSmithKline LLCRegistrant: GlaxoSmithKline plc | 893 River Road, Building 40, Conshohocken, Pennsylvania (PA) 19428, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging, sterilize | 3004055938929301406 |
| Corixa CorporationRegistrant: GlaxoSmithKline Biologicals SA | 325 North Bridge Street, Marietta, Pennsylvania (PA) 17547, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging, sterilize | 3007726770011553920 |
| GlaxoSmithKline LLCRegistrant: GlaxoSmithKline plc | 1011 North Arendell Ave, Zebulon, North Carolina (NC) 27597, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 1033964149372109 |
Alert
Drug shortage listings
3| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Fluticasone Propionate and Salmeterol Xinafoate Aerosol, MeteredPulmonary/Allergy | Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22) | To Be Discontinued | - | 27 Jul 202627 Jul 2026 |
| Fluticasone Propionate and Salmeterol Xinafoate Aerosol, MeteredPulmonary/Allergy | Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22) | To Be Discontinued | - | 27 Jul 202627 Jul 2026 |
| Fluticasone Propionate and Salmeterol Xinafoate Aerosol, MeteredPulmonary/Allergy | Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22) | To Be Discontinued | - | 27 Jul 202627 Jul 2026 |
Catalogue
Drug listings by form and route
126126 active NDC listings: 81 human prescription drug, 25 vaccine, 13 drug for further processing, 7 bulk ingredient. By marketing category: NDA 72, BLA 33, DRUG FOR FURTHER PROCESSING 13, BULK INGREDIENT 7, UNAPPROVED DRUG OTHER 1.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 26 |
| kit | 18 |
| powder | 13 |
| tablet, film coated, extended release | 10 |
| tablet | 9 |
| injection, suspension | 8 |
| liquid | 7 |
| injection, solution | 6 |
| suspension | 5 |
| aerosol, metered | 4 |
| injection | 4 |
| tablet, orally disintegrating | 4 |
| tablet, for suspension | 3 |
| injection, powder, for solution | 2 |
| injection, powder, lyophilized, for solution | 2 |
| Route | NDCs |
|---|---|
| oral | 45 |
| respiratory (inhalation) | 18 |
| intramuscular | 14 |
| subcutaneous | 8 |
| intravenous | 4 |
| Labeller name on the listing | NDCs |
|---|---|
| glaxosmithkline llc | 97 |
| glaxosmithkline biologicals sa | 25 |
| glaxosmithkline manufacturing spa | 4 |
Exclusivity
Patents and exclusivities
63| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8071579 | ZEJULAniraparib tosylate | use | Aug 2027 |
| 8143241 | ZEJULAniraparib tosylate | use | Aug 2027 |
| 8637512 | LAMICTAL XRlamotrigine | product | Jan 2029 |
| 8389524 | BLUJEPAgepotidacin mesylate | substance, product | Feb 2029 |
| 8436185 | ZEJULAniraparib tosylate | substance | Apr 2029 |
| 8188085 | BREXAFEMMEibrexafungerp citrate | substance, product | Aug 2030 |
| 8071623 | ZEJULAniraparib tosylate | substance, product | Mar 2031 |
| 8859562 | ZEJULAniraparib tosylate | use | Aug 2031 |
| 8486941 | OJJAARAmomelotinib dihydrochloride | substance, product | Jan 2035 |
| 10174074 | BREXAFEMMEibrexafungerp citrate | substance, product | Jan 2035 |
| 10370406 | BREXAFEMMEibrexafungerp citrate | use | Jan 2035 |
| 10927142 | BREXAFEMMEibrexafungerp citrate | substance | Jan 2035 |
| 9809559 | OJJAARAmomelotinib dihydrochloride | use | Jun 2035 |
| RE48285 | OJJAARAmomelotinib dihydrochloride | substance, product | Jun 2035 |
| 10702521 | BLUJEPAgepotidacin mesylate | use | Aug 2035 |
| 11229646 | BLUJEPAgepotidacin mesylate | use | Aug 2035 |
| 12226403 | UTEBZItebipenem pivoxil hydrobromide | product | Dec 2037 |
| 10889587 | UTEBZItebipenem pivoxil hydrobromide | substance, product | Feb 2038 |
| 11091459 | ZEJULAniraparib tosylate | product | Mar 2038 |
| 11673877 | ZEJULAniraparib tosylate | product | Mar 2038 |
| 11730725 | ZEJULAniraparib tosylate | product | Jan 2039 |
| 11534433 | BREXAFEMMEibrexafungerp citrate | use | Jun 2039 |
| 12576089 | OJJAARAmomelotinib dihydrochloride | use | Aug 2039 |
| 11963962 | OJJAARAmomelotinib dihydrochloride | use | Dec 2040 |
| 12528809 | BLUJEPAgepotidacin mesylate | substance, product | Dec 2042 |
| Product | Exclusivity | Until |
|---|---|---|
| BLUJEPAGEPOTIDACIN MESYLATE | GAIN Qualified infectious disease product (GAIN) | Mar 2035 |
| BREXAFEMMEIBREXAFUNGERP CITRATE | GAIN Qualified infectious disease product (GAIN) | Jun 2031 |
| OJJAARAMOMELOTINIB DIHYDROCHLORIDE | ODE-441 Orphan drug | Sept 2030 |
| UTEBZITEBIPENEM PIVOXIL HYDROBROMIDE | GAIN Qualified infectious disease product (GAIN) | Jun 2036 |
| ZEJULANIRAPARIB TOSYLATE | ODE-295 Orphan drug | Apr 2027 |
Catalogue
Marketed products
126| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ADVAIR DISKUS | fluticasone propionate and salmeterol | powder, respiratory (inhalation) | 0173-0695NDA |
| ADVAIR DISKUS | fluticasone propionate and salmeterol | powder, respiratory (inhalation) | 0173-0696NDA |
| ADVAIR DISKUS | fluticasone propionate and salmeterol | powder, respiratory (inhalation) | 0173-0697NDA |
| ADVAIR HFA | fluticasone propionate and salmeterol xinafoate | aerosol, metered, respiratory (inhalation) | 0173-0715NDA |
| ADVAIR HFA | fluticasone propionate and salmeterol xinafoate | aerosol, metered, respiratory (inhalation) | 0173-0716NDA |
| ADVAIR HFA | fluticasone propionate and salmeterol xinafoate | aerosol, metered, respiratory (inhalation) | 0173-0717NDA |
| AS03 | AS03 | injection, solution, intramuscular | 58160-855UNAPPROVED DRUG OTHER |
| Anoro Ellipta | umeclidinium bromide and vilanterol trifenatate | powder, respiratory (inhalation) | 0173-0869NDA |
| Arepanrix | Influenza A H5 Monovalent Vaccine | kit | 58160-742BLA |
| Arexvy | Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted | kit | 58160-848BLA |
| Arexvy | Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted | kit | 58160-882BLA |
| Arexvy | Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted | kit | 58160-894BLA |
| Arnuity Ellipta | fluticasone furoate | powder, respiratory (inhalation) | 0173-0874NDA |
| Arnuity Ellipta | fluticasone furoate | powder, respiratory (inhalation) | 0173-0876NDA |
| Arnuity Ellipta | fluticasone furoate | powder, respiratory (inhalation) | 0173-0888NDA |
| BENLYSTA | belimumab | solution, subcutaneous | 49401-088BLA |
| BENLYSTA | belimumab | injection, powder, lyophilized, for solution, intravenous | 49401-101BLA |
| BENLYSTA | belimumab | injection, powder, lyophilized, for solution, intravenous | 49401-102BLA |
| BOOSTRIX | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed | suspension, intramuscular | 58160-842BLA |
| Bexsero | NEISSERIA MENINGITIDIS SEROGROUP B NHBA FUSION PROTEIN ANTIGEN, NEISSERIA MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN ANTIGEN and NEISSERIA MENINGITIDIS SEROGROUP B NADA PROTEIN ANTIGEN | injection, suspension, intramuscular | 58160-976BLA |
| Blenrep | belantamab mafodotin | injection, powder, for solution, intravenous | 0173-0913BLA |
| Blujepa | gepotidacin | tablet, film coated, oral | 0173-0922NDA |
| Breo Ellipta | fluticasone furoate and vilanterol trifenatate | powder, respiratory (inhalation) | 0173-0859NDA |
| Breo Ellipta | fluticasone furoate and vilanterol trifenatate | powder, respiratory (inhalation) | 0173-0882NDA |
| Breo Ellipta | fluticasone furoate and vilanterol trifenatate | powder, respiratory (inhalation) | 0173-0916NDA |
| - | Depemokimab | liquid | 58437-029BULK INGREDIENT |
| - | Dolutegravir and Lamivudine | tablet, film coated | 58437-027DRUG FOR FURTHER PROCESSING |
| ENGERIX-B | Hepatitis B Vaccine (Recombinant) | injection, suspension, intramuscular | 58160-820BLA |
| ENGERIX-B | Hepatitis B Vaccine (Recombinant) | injection, suspension, intramuscular | 58160-821BLA |
| Exdensur | depemokimab | injection, solution, subcutaneous | 0173-0927BLA |
| FLUARIX 2026/2027 | influenza virus vaccine | suspension, intramuscular | 58160-725BLA |
| HAVRIX | Hepatitis A Vaccine | injection, suspension, intramuscular | 58160-825BLA |
| HAVRIX | Hepatitis A Vaccine | injection, suspension, intramuscular | 58160-826BLA |
| Hiberix | Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) | kit | 58160-726BLA |
| Hiberix | Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) | kit | 58160-818BLA |
| IMITREX | sumatriptan | injection, subcutaneous | 0173-0478NDA |
| IMITREX | sumatriptan | injection, subcutaneous | 0173-0479NDA |
| IMITREX | sumatriptan | tablet, film coated, oral | 0173-0735NDA |
| IMITREX | sumatriptan | tablet, film coated, oral | 0173-0736NDA |
| IMITREX | sumatriptan | tablet, film coated, oral | 0173-0737NDA |
| IMITREX | sumatriptan | injection, subcutaneous | 0173-0739NDA |
| INFANRIX | Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed | suspension, intramuscular | 58160-810BLA |
| Incruse Ellipta | umeclidinium | aerosol, powder, oral | 0173-0873NDA |
| Jemperli | dostarlimab | injection, intravenous | 0173-0898BLA |
| Jesduvroq | daprodustat | tablet, film coated, oral | 0173-0897NDA |
| Jesduvroq | daprodustat | tablet, film coated, oral | 0173-0903NDA |
| Jesduvroq | daprodustat | tablet, film coated, oral | 0173-0906NDA |
| Jesduvroq | daprodustat | tablet, film coated, oral | 0173-0911NDA |
| Jesduvroq | daprodustat | tablet, film coated, oral | 0173-0914NDA |
| KINRIX | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine | injection, suspension, intramuscular | 58160-812BLA |
| Krintafel | tafenoquine succinate | tablet, film coated, oral | 0173-0889NDA |
| LAMICTAL | lamotrigine | tablet, for suspension, oral | 0173-0526NDA |
| LAMICTAL | lamotrigine | tablet, for suspension, oral | 0173-0527NDA |
| LAMICTAL | lamotrigine | kit | 0173-0594NDA |
| LAMICTAL | lamotrigine | tablet, oral | 0173-0633NDA |
| LAMICTAL | lamotrigine | tablet, oral | 0173-0642NDA |
| LAMICTAL | lamotrigine | tablet, oral | 0173-0643NDA |
| LAMICTAL | lamotrigine | tablet, oral | 0173-0644NDA |
| LAMICTAL | lamotrigine | tablet, for suspension, oral | 0173-0699NDA |
| LAMICTAL | lamotrigine | kit | 0173-0817NDA |
| LAMICTAL ODT | lamotrigine | tablet, orally disintegrating, oral | 0173-0772NDA |
| LAMICTAL ODT | lamotrigine | tablet, orally disintegrating, oral | 0173-0774NDA |
| LAMICTAL ODT | lamotrigine | tablet, orally disintegrating, oral | 0173-0776NDA |
| LAMICTAL ODT | lamotrigine | tablet, orally disintegrating, oral | 0173-0777NDA |
| LAMICTAL ODT | lamotrigine | kit | 0173-0778NDA |
| LAMICTAL ODT | lamotrigine | kit | 0173-0779NDA |
| LAMICTAL ODT | lamotrigine | kit | 0173-0780NDA |
| LAMICTAL XR | lamotrigine | tablet, film coated, extended release, oral | 0173-0754NDA |
| LAMICTAL XR | lamotrigine | tablet, film coated, extended release, oral | 0173-0755NDA |
| LAMICTAL XR | lamotrigine | tablet, film coated, extended release, oral | 0173-0756NDA |
| LAMICTAL XR | lamotrigine | tablet, film coated, extended release, oral | 0173-0757NDA |
| LAMICTAL XR | lamotrigine | kit | 0173-0758NDA |
| LAMICTAL XR | lamotrigine | kit | 0173-0759NDA |
| LAMICTAL XR | lamotrigine | kit | 0173-0760NDA |
| LAMICTAL XR | lamotrigine | tablet, film coated, extended release, oral | 0173-0761NDA |
| LAMICTAL XR | lamotrigine | tablet, film coated, extended release, oral | 0173-0781NDA |
| MALARONE | atovaquone and proguanil hydrochloride | tablet, film coated, oral | 0173-0675NDA |
| MALARONE | atovaquone and proguanil hydrochloride | tablet, film coated, oral | 0173-0676NDA |
| MEPRON | atovaquone | suspension, oral | 0173-0547NDA |
| MEPRON | atovaquone | suspension, oral | 0173-0665NDA |
| Menveo | Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine | injection, solution, intramuscular | 58160-827BLA |
| Menveo | Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine | kit | 58160-955BLA |
| Nucala | mepolizumab | injection, powder, for solution, subcutaneous | 0173-0881BLA |
| Nucala | mepolizumab | injection, solution, subcutaneous | 0173-0892BLA |
| Nucala | mepolizumab | injection, solution, subcutaneous | 0173-0904BLA |
| Ojjaara | Momelotinib | tablet, oral | 81864-101NDA |
| Ojjaara | Momelotinib | tablet, oral | 81864-102NDA |
| Ojjaara | Momelotinib | tablet, oral | 81864-103NDA |
| PEDIARIX | Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined | injection, suspension, intramuscular | 58160-811BLA |
| PENMENVY | Meningococcal (Groups A, B, C, W and Y) | kit | 58160-757BLA |
| Priorix | Measels, Mumps, and Rubella Vaccine, Live | kit | 58160-824BLA |
| RELENZA | zanamivir | powder, respiratory (inhalation) | 0173-0681NDA |
| Rotarix | Rotavirus Vaccine, Live, Oral | solution, oral | 58160-740BLA |
| SEREVENT DISKUS | salmeterol xinafoate | powder, metered, oral, respiratory (inhalation) | 0173-0521NDA |
| Shingrix | Zoster Vaccine Recombinant, Adjuvanted | kit | 58160-823BLA |
| Shingrix | Zoster Vaccine Recombinant, Adjuvanted | injection, solution, intramuscular | 58160-849BLA |
| TWINRIX | Hepatitis A and Hepatitis B (Recombinant) Vaccine | injection, suspension, intramuscular | 58160-815BLA |
| Trelegy Ellipta | fluticasone furoate, umeclidinium bromide and vilanterol trifenatate | powder, respiratory (inhalation) | 0173-0887NDA |
| Trelegy Ellipta | fluticasone furoate, umeclidinium bromide and vilanterol trifenatate | powder, respiratory (inhalation) | 0173-0893NDA |
| VALTREX | valacyclovir hydrochloride | tablet, film coated, oral | 0173-0565NDA |
| VALTREX | valacyclovir hydrochloride | tablet, film coated, oral | 0173-0933NDA |
| VENTOLIN HFA | albuterol sulfate | aerosol, metered, respiratory (inhalation) | 0173-0682NDA |
| WELLBUTRIN SR | bupropion hydrochloride | tablet, film coated, oral | 0173-0135NDA |
| WELLBUTRIN SR | bupropion hydrochloride | tablet, film coated, oral | 0173-0722NDA |
| WELLBUTRIN SR | bupropion hydrochloride | tablet, film coated, oral | 0173-0947NDA |
| ZEJULA | niraparib | tablet, film coated, oral | 0173-0909NDA |
| ZEJULA | niraparib | tablet, film coated, oral | 0173-0912NDA |
| ZEJULA | niraparib | tablet, film coated, oral | 0173-0915NDA |
| - | belantamab mafodotin | liquid | 12064-026BULK INGREDIENT |
| - | belimumab | liquid | 49401-000BULK INGREDIENT |
| - | doxorubicin hydrochloride | injection, suspension, liposomal | 12064-019DRUG FOR FURTHER PROCESSING |
| - | lamotrigine | tablet, film coated, extended release | 58437-019DRUG FOR FURTHER PROCESSING |
| - | lamotrigine | tablet, film coated, extended release | 58437-020DRUG FOR FURTHER PROCESSING |
| - | lamotrigine | tablet, film coated, extended release | 58437-021DRUG FOR FURTHER PROCESSING |
| - | lamotrigine | tablet, film coated, extended release | 58437-022DRUG FOR FURTHER PROCESSING |
| - | lamotrigine | tablet | 58437-023DRUG FOR FURTHER PROCESSING |
| - | lamotrigine | tablet | 58437-024DRUG FOR FURTHER PROCESSING |
| - | mepolizumab | liquid | 49401-012BULK INGREDIENT |
| - | mepolizumab | liquid | 58437-004BULK INGREDIENT |
| - | mepolizumab | liquid | 58437-009BULK INGREDIENT |
| - | raxibacumab | liquid | 49401-080BULK INGREDIENT |
| - | sumatriptan | tablet, film coated | 58437-016DRUG FOR FURTHER PROCESSING |
| - | sumatriptan | tablet, film coated | 58437-017DRUG FOR FURTHER PROCESSING |
| - | sumatriptan | tablet, film coated | 58437-018DRUG FOR FURTHER PROCESSING |
| - | trametinib | tablet, film coated | 12064-021DRUG FOR FURTHER PROCESSING |
| - | trametinib | tablet, film coated | 12064-022DRUG FOR FURTHER PROCESSING |
Neighbours
Registered in the same town
5- CSL LimitedMarburg, DEU
- BioNTech Manufacturing GmbHMarburg, DEU
- Sharp Packaging Services, LLCConshohocken, PA
- AmerisourceBergen Drug CorporationConshohocken, PA
- Autolus Inc.Stevenage, GBR
Compare
Comparable companies in United Kingdom
- Almac Pharma Services (Ireland) Limited7 sites · 1 NDC
- Oxford Biomedica (UK) Limited4 sites · 0 NDC
- Croda Europe Ltd.3 sites · 51 NDC
- DSM Nutritional Products France SAS3 sites · 30 NDC
- Labcorp Early Development Laboratories Inc3 sites · 0 NDC
- PhibroChem3 sites · 0 NDC
- Smithers MSE Limited3 sites · 0 NDC
- Valneva Austria GmbH3 sites · 0 NDC
- ACCORD HEALTHCARE LIMITED2 sites · 242 NDC
- Mondelez Global LLC2 sites · 27 NDC
Enquiry
Common questions
- Is GlaxoSmithKline Biologicals SA FDA approved?
- GlaxoSmithKline Biologicals SA holds 19 FDA-registered establishments across 9 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are GlaxoSmithKline Biologicals SA's drugs manufactured?
- At registered sites in Belgium, Canada, Germany, Spain, France, the United Kingdom and 3 other countries. The FDA register lists Rixensart; Wavre; Ste-Foy; Dresden; Marburg; Aranda De Duero, and 13 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging, particle size reduction, sterilize.
- What drugs does GlaxoSmithKline Biologicals SA make?
- 126 products are listed under GlaxoSmithKline Biologicals SA in the openFDA NDC Directory, most often as tablet, film coated; kit; powder. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.